Pasar al contenido principal

EL TRATAMIENTO ANTIOXIDANTE COMO UNA NUEVA OPCION TERAPEUTICA PARA LA ENFERMEDAD DE INCLUSION DE MICROVELLOSIDADES

AC20/00022

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Programación Conjunta Internacional
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)
Centro realización INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis

  • Bazzocco, Sarah
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Anguita, Estefanía|||0000-0003-2230-7030
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Li, Jing|||0000-0002-9283-3821
  • Garcia-Vidal, Elia|||0000-0002-2756-9438
  • Maggio, Valentina|||0000-0002-4985-5611
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Schwartz, Simon|||0000-0001-8297-7971
  • Aaltonen, Lauri A.|||0000-0001-6839-4286
  • Sánchez, Alex|||0000-0002-8673-7737
  • Mariadason, John M.|||0000-0001-9123-7684
  • Arango, Diego|||0000-0003-2953-3284
Cancer initiation and progression are driven by genetic and epigenetic changes. Although genome/exome sequencing has significantly contributed to the characterization of the genetic driver alterations, further investigation is required to systematically identify cancer driver genes regulated by promoter hypermethylation. Using genome-wide analysis of promoter methylation in 45 colorectal cancer cell lines, we found that higher overall methylation levels were associated with microsatellite instability (MSI), faster proliferation and absence of APC mutations. Because epigenetically silenced genes could represent important oncogenic drivers, we used mRNA expression profiling of colorectal cancer cell lines and primary tumors to identify a subset of 382 (3.9%) genes for which promoter methylation was negatively associated with gene expression. Remarkably, a significant enrichment in zinc finger proteins was observed, including the transcriptional repressor ZBTB18. Re-introduction of ZBTB18 in colon cancer cells significantly reduced proliferation in vitro and in a subcutaneous xenograft mouse model. Moreover, immunohistochemical analysis revealed that ZBTB18 is frequently lost or reduced in colorectal tumors, and reduced ZBTB18 expression was found to be associated with lymph node metastasis and shorter survival of patients with locally advanced colorectal cancer. We identified a set of 382 genes putatively silenced by promoter methylation in colorectal cancer that could significantly contribute to the oncogenic process. Moreover, as a proof of concept, we demonstrate that the epigenetically silenced gene ZBTB18 has tumor suppressor activity and is a novel prognostic marker for patients with locally advanced colorectal cancer. The online version contains supplementary material available at 10.1186/s13148-021-01070-0.